If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02674581","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"Healthy Subjects","arm_group_description":"A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.","arm_type":"Experimental"},{"arm_group_label":"Mild Renal Impairment Subjects","arm_group_description":"A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.","arm_type":"Experimental"},{"arm_group_label":"Moderate Renal Impairment Subjects","arm_group_description":"A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.","arm_type":"Experimental"},{"arm_group_label":"Severe Renal Impairment Subjects","arm_group_description":"A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.","arm_type":"Experimental"},{"arm_group_label":"End Stage Renal Disease Subjects","arm_group_description":"A single dose of pro-drug, BMS-663068, administered orally and then metabolized to active BMS-626529 on Day 1.","arm_type":"Experimental"}],"assignment":"Parallel Assignment","brief_summary":"An oral dose in healthy and renally impaired subjects to determine the drug effect for BMS-663068.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects with Normal Renal Function and with Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"HIV infections","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:22:11","criteria":"Inclusion Criteria (For renal impaired subjects): • Classification by renal function based on eGFR • Clinical, ECG, and laboratory findings consistent with renal dysfunction • BMI of 18.0 to 38.0 kg/m2 inclusive • Women of child bearing potential (WOCBP) and sexually active fertile men with partners who are WOCBP must use non-hormonal highly effective birth control • Slightly different inclusion criteria are defined in the protocol for healthy subjects Exclusion Criteria: - History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening - Evidence of rapidly deteriorating renal function, defined as a screening eGFR that has decreased from a previous eGFR by ≥ 50% within the last 3 months - Current or recent (within 3 months of study drug administration) clinically significant gastrointestinal disease or gastrointestinal surgery (including cholecystectomy) that could impact the absorption of study drug - Any major surgery within 4 weeks of study drug administration. - Other protocol defined exclusion criteria could apply","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 1","display_phase_internal":"PHASE_1","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"30","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"Yes","id":"9979a08e-2654-54ad-80f4-fdd1b785c2a3","internal":{"content":null,"contentDigest":"a0ba9a5d1869af78e9c0830e76e0912b","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria (For renal impaired subjects): • Classification by renal function based on eGFR • Clinical, ECG, and laboratory findings consistent with renal dysfunction • BMI of 18.0 to 38.0 kg/m2 inclusive • Women of child bearing potential (WOCBP) and sexually active fertile men with partners who are WOCBP must use non-hormonal highly effective birth control • Slightly different inclusion criteria are defined in the protocol for healthy subjects Exclusion Criteria: - History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric, and/or neurological disease within 6 months of screening - Evidence of rapidly deteriorating renal function, defined as a screening eGFR that has decreased from a previous eGFR by ≥ 50% within the last 3 months - Current or recent (within 3 months of study drug administration) clinically significant gastrointestinal disease or gastrointestinal surgery (including cholecystectomy) that could impact the absorption of study drug - Any major surgery within 4 weeks of study drug administration. - Other protocol defined exclusion criteria could apply","interventions":[{"arm_group_label":"End Stage Renal Disease Subjects","intervention_description":"Oral BMS-663068 (pro-drug), metabolized to active BMS-626529","intervention_name":"Oral BMS-663068 (pro-drug)","intervention_type":"Drug"},{"arm_group_label":"Mild Renal Impairment Subjects","intervention_description":"Oral BMS-663068 (pro-drug), metabolized to active BMS-626529","intervention_name":"Oral BMS-663068 (pro-drug)","intervention_type":"Drug"},{"arm_group_label":"Severe Renal Impairment Subjects","intervention_description":"Oral BMS-663068 (pro-drug), metabolized to active BMS-626529","intervention_name":"Oral BMS-663068 (pro-drug)","intervention_type":"Drug"},{"arm_group_label":"Moderate Renal Impairment Subjects","intervention_description":"Oral BMS-663068 (pro-drug), metabolized to active BMS-626529","intervention_name":"Oral BMS-663068 (pro-drug)","intervention_type":"Drug"},{"arm_group_label":"Healthy Subjects","intervention_description":"Oral BMS-663068 (pro-drug), metabolized to active BMS-626529","intervention_name":"Oral BMS-663068 (pro-drug)","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":[],"last_follow_up_date":"05/24/2016 00:00:00","links":[],"locations":[{"City":"Miami","Latitude":"25.9109586","CountryDisplay":"United States","Longitude":"-80.3045967","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33014","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:43:48","number_of_arms":"5","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"An Open-label Study to Evaluate the Pharmacokinetics and Safety of BMS-663068 in Subjects with Normal Renal Function and Subjects with Mild, Moderate, Severe, and End‑stage Renal Dysfunction","org_study_id":"206217","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"1","primary_compl_date":"05/24/2016 00:00:00","primary_outcomes":[{"outcome_description":"To assess the effect of varying degrees of renal impairment on the exposure of BMS-626529 after a single oral-dose administration of the pro-drug, BMS-663068, will be evaluated by assessing the primary endpoints of Cmax, for BMS-626529.","outcome_measure":"Effect of Renal Impairment on The Primary Endpoints of Cmax","outcome_time_frame":"Day 1 - Day 5","outcome_safety_issue":null}],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[{"id":"AI438-070","id_type":"Other Identifier","id_domain":"Bristol-Myers Squibb"}],"secondary_outcomes":[{"outcome_description":"To assess the safety and tolerability of BMS-663068 in subjects with normal renal function and subjects with impaired renal functions, will be measured by the following secondary endpoints: Incidence of AEs, Serious Adverse Events (SAEs), and AEs leading to discontinuation, and results of vital signs, ECGs, physical examination, and clinical laboratory tests.","outcome_measure":"Safety and Tolerability as assessed by the Incidence of Serious Adverse Events (SAEs), Adverse Events (AEs), AEs leading to discontinuation, and the results of ECGs, vital signs, physical examination, and clinical laboratory tests.","outcome_time_frame":"Day 1 - Day 5","outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["GlaxoSmithKline"]},"start_date":"02/26/2016 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":true}},"pageContext":{"studyId":"206217"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}